KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Net Income (2016 - 2025)

Historic Net Income for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to -$7.7 million.

  • Arbutus Biopharma's Net Income rose 6080.52% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.3 million, marking a year-over-year increase of 4489.46%. This contributed to the annual value of -$69.9 million for FY2024, which is 402.06% up from last year.
  • According to the latest figures from Q3 2025, Arbutus Biopharma's Net Income is -$7.7 million, which was up 6080.52% from $2.5 million recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Net Income registered a high of $2.5 million during Q2 2025, and its lowest value of -$24.5 million during Q1 2025.
  • Moreover, its 5-year median value for Net Income was -$17.9 million (2024), whereas its average is -$16.7 million.
  • Per our database at Business Quant, Arbutus Biopharma's Net Income plummeted by 3762.33% in 2021 and then skyrocketed by 11264.4% in 2025.
  • Arbutus Biopharma's Net Income (Quarter) stood at -$21.3 million in 2021, then decreased by 2.87% to -$21.9 million in 2022, then increased by 11.95% to -$19.3 million in 2023, then surged by 35.28% to -$12.5 million in 2024, then skyrocketed by 38.16% to -$7.7 million in 2025.
  • Its Net Income was -$7.7 million in Q3 2025, compared to $2.5 million in Q2 2025 and -$24.5 million in Q1 2025.